

Arun Sahai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9421319/publications.pdf>

Version: 2024-02-01

121
papers

2,583
citations

236833

25
h-index

206029

48
g-index

122
all docs

122
docs citations

122
times ranked

2461
citing authors

#	ARTICLE	IF	CITATIONS
1	British Association of Urological Surgeons (BAUS) consensus document: Management of female voiding dysfunction. BJU International, 2022, 129, 151-159.	1.3	7
2	Pre-robotic prostatectomy membranous urethral length as a predictive factor of post prostatectomy incontinence requiring surgical intervention with an artificial urinary sphincter or a male sling. Neurourology and Urodynamics, 2022, 41, 973-979.	0.8	4
3	Does response to percutaneous tibial nerve stimulation predict similar outcome to sacral nerve stimulation?. Neurourology and Urodynamics, 2022, 41, 1172-1176.	0.8	3
4	Predictors of Poor Response and Adverse Events Following Botulinum Toxin A for Refractory Idiopathic Overactive Bladder: A Systematic Review. European Urology Focus, 2021, 7, 1448-1467.	1.6	12
5	Use of Duloxetine for Postprostatectomy Stress Urinary Incontinence: A Systematic Review. European Urology Focus, 2021, 7, 618-628.	1.6	18
6	Is pre-operative urodynamic bladder function the true predictor of outcome of male sling for post prostatectomy incontinence?. World Journal of Urology, 2021, 39, 1227-1232.	1.2	6
7	Cost Effectiveness of Sacral Neuromodulation and OnabotulinumtoxinA in Managing Refractory Idiopathic Overactive Bladder. Urology, 2021, 149, 1-10.	0.5	3
8	Shifting the treatment paradigm in idiopathic overactive bladder. International Journal of Clinical Practice, 2021, 75, e13847.	0.8	4
9	Bladder pain syndrome/interstitial cystitis in contemporary UK practice: Outcomes of phenotype-directed management. LUTS: Lower Urinary Tract Symptoms, 2021, 13, 123-128.	0.6	3
10	ATP shows more potential as a urinary biomarker than acetylcholine and PGE 2 , but its concentration in urine is not a simple function of dilution. Neurourology and Urodynamics, 2021, 40, 753-762.	0.8	1
11	Prevalence of chronic pain following suburethral mesh sling implantation for post-robotic prostatectomy incontinence. Neurourology and Urodynamics, 2021, 40, 1048-1055.	0.8	0
12	British Association of Urological Surgeons (BAUS) consensus document: management of bladder and ureteric injury. BJU International, 2021, 128, 539-547.	1.3	10
13	The MIC-KEY button vesicostomy: a superior alternative for suprapubic drainage?. BJU International, 2020, 125, 299-303.	1.3	0
14	Case-finding tools for the diagnosis of OAB in women: A narrative review. Neurourology and Urodynamics, 2020, 39, 13-24.	0.8	1
15	Predictors of Poor Response and Adverse Events Following Botulinum Toxin-A for Refractory Idiopathic Overactive Bladder. Urology, 2020, 135, 32-37.	0.5	13
16	Re: Marcus J. Drake, Amanda L. Lewis, Grace J. Young, et al. Diagnostic Assessment of Lower Urinary Tract Symptoms in Men Considering Prostate Surgery: A Noninferiority Randomised Controlled Trial of Urodynamics in 26 Hospitals. Eur Urol 2020;78:701-710. European Urology, 2020, 78, e232-e233.	0.9	2
17	Phenotypes of BPS/IC. Current Bladder Dysfunction Reports, 2020, 15, 203-213.	0.2	1
18	<p></p>Clinical Management of Bladder Pain Syndrome/Interstitial Cystitis: A Review on Current Recommendations and Emerging Treatment Options</p>. Research and Reports in Urology, 2020, Volume 12, 331-343.	0.6	22

#	ARTICLE	IF	CITATIONS
19	Clear cell carcinoma in a urethral diverticulum. <i>Urology Case Reports</i> , 2020, 32, 101164.	0.1	2
20	Total Pelvic Exenteration for Locally Advanced and Recurrent Rectal Cancer: Urological Outcomes and Adverse Events. <i>European Urology Focus</i> , 2020, 7, 638-643.	1.6	2
21	Time for a botulinum toxin passport?. <i>Neurourology and Urodynamics</i> , 2020, 39, 2546-2549.	0.8	1
22	Applications of electromotive drug administration in urology. <i>Urology Annals</i> , 2020, 12, 301.	0.3	7
23	A national UK audit of suprapubic catheter insertion practice and rate of bowel injury with comparison to a systematic review and meta-analysis of available research. <i>Neurourology and Urodynamics</i> , 2019, 38, 2194-2199.	0.8	11
24	How can we improve the diagnosis and management of bladder pain syndrome? Part 1: ICIERS 2018. <i>Neurourology and Urodynamics</i> , 2019, 38, S66-S70.	0.8	4
25	Female stress urinary incontinence MDT. <i>Journal of Clinical Urology</i> , 2019, 12, 255-265.	0.1	1
26	How can we improve the diagnosis and management of bladder pain syndrome? Part 2: ICIERS 2018. <i>Neurourology and Urodynamics</i> , 2019, 38, S71-S81.	0.8	8
27	How can we prevent postprostatectomy urinary incontinence by patient selection, and by preoperative, peroperative, and postoperative measures? International Consultation on Incontinence Research Society 2018. <i>Neurourology and Urodynamics</i> , 2019, 38, S119-S126.	0.8	12
28	How can we better manage drug-resistant OAB/DO? ICIERS 2018. <i>Neurourology and Urodynamics</i> , 2019, 38, S46-S55.	0.8	6
29	Onabotulinum toxin A Injections in Men With Refractory Idiopathic Detrusor Overactivity. <i>Urology</i> , 2019, 123, 242-246.	0.5	21
30	The role of dry-lab and cadaveric simulation for cystoscopy and intravesical Botulinum toxin injections. <i>Translational Andrology and Urology</i> , 2019, 8, 673-677.	0.6	3
31	Re: Long-Term Treatment with OnabotulinumtoxinA Results in Consistent, Durable Improvements in Health Related Quality of Life in Patients with Overactive Bladder. <i>Journal of Urology</i> , 2018, 199, 856-858.	0.2	0
32	Urethral Sphincter Injection of Botulinum Toxin A: Review of Its Application and Outcomes. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2018, 10, 109-115.	0.6	6
33	Feasibility of using a novel non-invasive ambulatory tibial nerve stimulation device for the home-based treatment of overactive bladder symptoms. <i>Translational Andrology and Urology</i> , 2018, 7, 912-919.	0.6	22
34	Nonantibiotic prevention and management of recurrent urinary tract infection. <i>Nature Reviews Urology</i> , 2018, 15, 750-776.	1.9	155
35	Guideline of guidelines: bladder pain syndrome. <i>BJU International</i> , 2018, 122, 729-743.	1.3	79
36	What is the exact working mechanism of botulinum toxin A and sacral nerve stimulation in the treatment of overactive bladder/detrusor overactivity? ICIERS 2017. <i>Neurourology and Urodynamics</i> , 2018, 37, S108-S116.	0.8	22

#	ARTICLE	IF	CITATIONS
37	Persistence with mirabegron therapy for overactive bladder: A real life experience. <i>Neurourology and Urodynamics</i> , 2017, 36, 404-408.	0.8	30
38	The dilemma with comparing efficacy of OAB treatments. <i>Nature Reviews Urology</i> , 2017, 14, 393-394.	1.9	0
39	The role of male slings in post prostatectomy incontinence: ICIâ€RS 2015. <i>Neurourology and Urodynamics</i> , 2017, 36, 927-934.	0.8	12
40	Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICIâ€RS 2015). <i>Neurourology and Urodynamics</i> , 2017, 36, 882-893.	0.8	44
41	Mixed urinary incontinence- what should we treat first?. <i>Journal of Clinical Urology</i> , 2017, 10, 492-499.	0.1	1
42	Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder. <i>Therapeutic Advances in Urology</i> , 2017, 9, 3-10.	0.9	24
43	Urethral atrophy is fiction! Time to focus on the capsule?. <i>BJU International</i> , 2016, 117, 549-550.	1.3	0
44	Do we understand how botulinum toxin works and have we optimized the way it is administered to the bladder? ICI-RS 2014. <i>Neurourology and Urodynamics</i> , 2016, 35, 293-298.	0.8	20
45	The Artificial Urinary Sphincter. , 2016, , 145-160.		0
46	Getting out of a tight spot: an overview of ureteroenteric anastomotic strictures. <i>Nature Reviews Urology</i> , 2016, 13, 447-455.	1.9	36
47	Bilateral ureteric obstruction during in vitro fertilisation therapy in a patient with complex surgically managed Crohn's disease. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016216956.	0.2	0
48	Integrative review on the nonâ€invasive management of lower urinary tract symptoms in men following treatments for pelvic malignancies. <i>International Journal of Clinical Practice</i> , 2015, 69, 1184-1208.	0.8	12
49	Patient experience and satisfaction with Onabotulinumtoxin A for refractory overactive bladder. <i>BJU International</i> , 2015, 116, 443-449.	1.3	20
50	The Relationship Between Technical And Nontechnical Skills Within A Simulation-Based Ureteroscopy Training Environment. <i>Journal of Surgical Education</i> , 2015, 72, 1039-1044.	1.2	54
51	SINGLE CENTRE RANDOMISED PILOT STUDY OF TWO REGIMENS (30 MINS DAILY OR 30 MINS WEEKLY FOR 12) Tj ETQq1 1 0.784314 SCLEROSIS-RELATED OVERACTIVE BLADDER SYMPTOMS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, e4.20-e4.	0.9	3
52	Simulation-Based Ureteroscopy Training: A Systematic Review. <i>Journal of Surgical Education</i> , 2015, 72, 135-143.	1.2	55
53	Simulation-based ureteroscopy skills training curriculum with integration of technical and non-technical skills: a randomised controlled trial. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2015, 29, 2728-2735.	1.3	54
54	PDE-5 Inhibitors for BPH-Associated LUTS. <i>Current Drug Targets</i> , 2015, 16, 1180-1186.	1.0	8

#	ARTICLE	IF	CITATIONS
55	Efficacy of flexible ureteroscopy and laser lithotripsy for lower pole renal calculi. Journal of Clinical Urology, 2014, 7, 389-393.	0.1	1
56	Assessment of treatment-seeking behavior and healthcare utilization in an international cohort of subjects with overactive bladder. Current Medical Research and Opinion, 2014, 30, 1557-1564.	0.9	11
57	Validation of the bladder control self-assessment questionnaire (<sc>B</sc>-<sc>SAQ</sc>) in men. BJU International, 2014, 113, 783-788.	1.3	17
58	The changing face of urinary continence surgery in <sc>E</sc>ngland: a perspective from the <sc>H</sc>ospital <sc>E</sc>pisode <sc>S</sc>tistics database. BJU International, 2014, 114, 268-277.	1.3	32
59	Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction. BJU International, 2014, 113, 789-794.	1.3	95
60	What is the role for biomarkers for lower urinary tract disorders? ICI-RS 2013. Neurourology and Urodynamics, 2014, 33, 602-605.	0.8	27
61	Intravesical Therapy for Refractory Overactive Bladder and Detrusor Overactivity in Adults: Botulinum Toxin-A. Current Clinical Urology, 2014, , 135-154.	0.0	0
62	Botulinum Toxin-What Urologic Uses Does the Data Support?. Current Urology Reports, 2013, 14, 227-234.	1.0	8
63	Current State of the Art in Non-Invasive Urodynamics. Current Bladder Dysfunction Reports, 2013, 8, 83-91.	0.2	5
64	Botulinum toxin-A for overactive bladder: formulations, dosing and clean intermittent catheterisation. BJU International, 2013, 112, 9-10.	1.3	0
65	Is Percutaneous Nephrolithotomy in Solitary Kidneys Safe?. Urology, 2013, 82, 1013-1016.	0.5	18
66	Botulinum toxin-A for the treatment of overactive bladder: UK contributions. Journal of Clinical Urology, 2013, 6, 77-83.	0.1	6
67	Recent advances in the diagnosis and treatment of bladder cancer. BMC Medicine, 2013, 11, 13.	2.3	142
68	The use of botulinum toxin for the treatment of urologic pain. Current Opinion in Urology, 2013, 23, 570-578.	0.9	8
69	Nerve growth factor (<sc>NGF</sc>): a potential urinary biomarker for overactive bladder syndrome (<sc>OAB</sc>)? BJU International, 2013, 111, 372-380.	1.3	68
70	Renal Stone on USS/X-Ray. , 2013, , 167-173.		0
71	Should we inject the trigone during botulinum toxin injection?. Nature Reviews Urology, 2012, 9, 129-130.	1.9	1
72	Overactive bladder and sexual function: a nightmare couple. BJU International, 2012, 110, 921-924.	1.3	11

#	ARTICLE	IF	CITATIONS
73	Bipolar Transurethral Resection of Prostate: Current Status in the Management of Bladder Outflow Obstruction. <i>British Journal of Medical and Surgical Urology</i> , 2012, 5, 105-110.	0.2	2
74	Overactive bladder in men: initial assessment. <i>Trends in Urology & Men's Health</i> , 2012, 3, 7-12.	0.2	1
75	Overactive bladder in men: treatment options. <i>Trends in Urology & Men's Health</i> , 2012, 3, 13-16.	0.2	0
76	The psychology of LUTS: ICI&E RS 2011. <i>Neurourology and Urodynamics</i> , 2012, 31, 340-343.	0.8	26
77	Lower Urinary Tract Dysfunction in Multiple Sclerosis. <i>Current Bladder Dysfunction Reports</i> , 2012, 7, 97-104.	0.2	2
78	Repeated Botulinum Toxin Type A Injections for Refractory Overactive Bladder: Medium-Term Outcomes, Safety Profile, and Discontinuation Rates. <i>European Urology</i> , 2012, 61, 834-839.	0.9	120
79	Parallel Incisions Procedure for Penile Curvature&E"Short Term Outcomes. <i>British Journal of Medical and Surgical Urology</i> , 2011, 4, 64-67.	0.2	0
80	Testicular pain as a presentation of Cowden syndrome. <i>Annals of the Royal College of Surgeons of England</i> , 2011, 93, e51-e52.	0.3	3
81	Role of laparoscopic nephrectomy for refractory hypertension in poorly functioning kidneys. <i>Annals of the Royal College of Surgeons of England</i> , 2011, 93, 25-26.	0.3	8
82	The safety and efficacy of botulinum toxin-A in the management of bladder oversensitivity: a randomised double-blind placebo-controlled trial. <i>International Journal of Clinical Practice</i> , 2011, 65, 698-704.	0.8	32
83	Neurogenic Detrusor Overactivity in Patients With Spinal Cord Injury: Evaluation and Management. <i>Current Urology Reports</i> , 2011, 12, 404-412.	1.0	32
84	Repeat botulinum toxin-A injections for treatment of adult detrusor overactivity. <i>Nature Reviews Urology</i> , 2010, 7, 661-667.	1.9	24
85	Repeated Injections of Botulinum Toxin-A for Idiopathic Detrusor Overactivity. <i>Urology</i> , 2010, 75, 552-558.	0.5	69
86	Endovascular management of grade V blunt renal trauma with associated splenic injury. <i>Nature Reviews Urology</i> , 2009, 6, 335-337.	1.9	7
87	Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin&E: is incomplete bladder emptying predictable?. <i>BJU International</i> , 2009, 103, 630-634.	1.3	46
88	Improvement in quality of life after botulinum toxin&E A injections for idiopathic detrusor overactivity: results from a randomized double&Eblind placebo&Econtrolled trial. <i>BJU International</i> , 2009, 103, 1509-1515.	1.3	74
89	Periurethral Non-animal Stabilized Hyaluronic Acid/Dextranomer Injections: Efficacy and Formation of Granuloma/Sterile Abscess. <i>Urology</i> , 2009, 74, 486-488.	0.5	4
90	Re: Eisenberg et al.: Endoscopic Management of Retained Foreign Bodies Following Flexible Ureterorenoscopy for Renal Calculi (<i>Urology</i> 2009;73:1189-1194). <i>Urology</i> , 2009, 74, 1380-1381.	0.5	0

#	ARTICLE	IF	CITATIONS
91	Periurethral Injections of Non-Animal Stabilised Hyaluronic Acid/Dextranomer Gel and Sterile Abscess Formation. British Journal of Medical and Surgical Urology, 2009, 2, 174-175.	0.2	0
92	Botulinum Toxin: An Effective Treatment for Urge Incontinence. , 2009, , 257-274.		0
93	Obstructive jaundice as a presenting symptom of metastatic carcinoma of the prostate. BMJ Case Reports, 2009, 2009, bcr0520091839-bcr0520091839.	0.2	0
94	Vesicoureteric reflux diagnosed by urethral catheterisation. BMJ Case Reports, 2009, 2009, bcr0520091842-bcr0520091842.	0.2	0
95	Botulinum Toxin: An Effective Treatment for Urge Incontinence. , 2009, , 257-274.		0
96	EFFICACY AND COMPLICATIONS OF INTRADETRUSOR INJECTION WITH BOTULINUM TOXIN A IN PATIENTS WITH REFRACTORY IDIOPATHIC DETRUSOR OVERACTIVITY. BJU International, 2008, 101, 515-516.	1.3	2
97	Urodynamic Assessment of Poor Responders After Botulinum Toxin-A Treatment for Overactive Bladder. Urology, 2008, 71, 455-459.	0.5	42
98	Contralateral Recurrence of Testicular Tumor: Which Patients Need Biopsy at Initial Presentation?. Current Urology, 2008, 2, 51-53.	0.4	0
99	Is botulinum A toxin an effective treatment for idiopathic detrusor overactivity and sensory urgency?. Nature Reviews Urology, 2007, 4, 136-137.	1.4	1
100	Laparoscopic Nephrectomy in a Patient with Ankylosing Spondylitis: Surgical and Anesthetic Challenges. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2007, 17, 223-225.	0.5	1
101	Laparoscopic Retroperitoneal Nephrectomy for Giant Hydronephrosis: When Simple Nephrectomy Isn't Simple. Journal of Endourology, 2007, 21, 437-440.	1.1	14
102	Botulinum toxin for detrusor overactivity and symptoms of overactive bladder: where we are now and where we are going. Nature Reviews Urology, 2007, 4, 379-386.	1.4	13
103	Efficacy of Botulinum Toxin-A for Treating Idiopathic Detrusor Overactivity: Results From a Single Center, Randomized, Double-Blind, Placebo Controlled Trial. Journal of Urology, 2007, 177, 2231-2236.	0.2	285
104	INFORMED CONSENT: ARE WE DELUDING OURSELVES? A RANDOMIZED CONTROLLED STUDY. BJU International, 2007, 99, 943-943.	1.3	2
105	BOTULINUM TOXIN A IN THE OVERACTIVE BLADDER: CURRENT STATUS AND FUTURE DIRECTIONS. BJU International, 2007, 99, 1549-1550.	1.3	1
106	Laparoscopic upper urinary tract surgery for benign and malignant conditions. Does aetiology have an effect on health-related quality of life?*. International Journal of Clinical Practice, 2007, 61, 2026-2029.	0.8	7
107	Evolution of transdermal oxybutynin in the treatment of overactive bladder. International Journal of Clinical Practice, 2007, 62, 167-170.	0.8	17
108	The overactive bladder: review of current pharmacotherapy in adults. Part 2: treatment options in cases refractory to anticholinergics. Expert Opinion on Pharmacotherapy, 2006, 7, 529-538.	0.9	13

#	ARTICLE	IF	CITATIONS
109	The overactive bladder: review of current pharmacotherapy in adults. Part 1: pathophysiology and anticholinergic therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 509-527.	0.9	7
110	Laparoscopic pyeloplasty and pyelopyelostomy for ureteropelvic junction obstruction in a duplicated collecting system. <i>Urology</i> , 2006, 67, 199.e9-199.e11.	0.5	7
111	Techniques for the intradetrusor administration of botulinum toxin. <i>BJU International</i> , 2006, 97, 675-678.	1.3	22
112	A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. <i>BJU International</i> , 2006, 97, 413-414.	1.3	10
113	Video consent: a pilot study of informed consent in laparoscopic urology and its impact on patient satisfaction. <i>Journal of the Society of Laparoendoscopic Surgeons</i> , 2006, 10, 21-5.	0.5	24
114	Eosinophilic cystitis and its management. <i>International Journal of Clinical Practice</i> , 2005, 59, 356-360.	0.8	56
115	Laparoscopic ureteroneocystostomy for benign lower ureteric stricture: case study and literature review. <i>International Journal of Clinical Practice</i> , 2005, 59, 115-117.	0.8	3
116	Laparoscopic Management of Cryptorchidism in Adults. <i>European Urology</i> , 2005, 48, 453-457.	0.9	17
117	Botulinum toxin for the treatment of lower urinary tract symptoms: A review. <i>Neurourology and Urodynamics</i> , 2005, 24, 2-12.	0.8	59
118	Is botulinum toxin type A a safe and effective treatment for neurogenic urinary incontinence?. <i>Nature Reviews Urology</i> , 2005, 2, 530-531.	1.4	1
119	Botulinum toxin: A new dimension in the treatment of lower urinary tract dysfunction. <i>Urology</i> , 2005, 65, 211.	0.5	5
120	Percutaneous versus Open Tendo Achillis Repair. <i>Foot and Ankle International</i> , 2004, 25, 215-218.	1.1	92
121	Attitudes of medical and dental students to dissection. <i>Clinical Anatomy</i> , 2003, 16, 165-172.	1.5	137